MedTrace Logo

A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel

NCT01722968 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2019-02-27

No results posted yet for this study

Summary

To explore molecular biomarkers and/or gene expression signatures that predict response to bevacizumab given in combination with paclitaxel as first line therapy in HER2 negative metastatic breast cancer (MBC).

Conditions

Interventions

DRUG

Bevacizumab

15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly

DRUG

Paclitaxel

80mg/m2 iv weekly

Sponsors & Collaborators

  • Theodoros Foukakis

    lead OTHER

Principal Investigators

  • Theodoros Foukakis, MD PhD · Karolinska University Hospital

  • Jonas Bergh, Professor · Karolinska University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2018-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01722968 on ClinicalTrials.gov